Silo Pharma Regains Nasdaq Compliance, Securing Listing Post-Reverse Split
Summary
Silo Pharma has successfully regained compliance with the Nasdaq minimum bid price requirement. This positive development follows the 1-for-15 reverse stock split that became effective on June 2nd, which was implemented to boost the share price. Maintaining its Nasdaq listing is crucial for the micro-cap company's access to capital and investor confidence, removing the immediate threat of delisting.
At the time of this announcement, SILO was trading at $5.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3M. The 52-week trading range was $3.32 to $15.15. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.